Effectiveness of therapy with iloprost in hand-arm vibration syndrome.

Author: LeddaRoberto, MeloniMichele, TorrazzaMario

Paper Details 
Original Abstract of the Article :
AIM: To evaluate the efficacy and tolerance of therapy with iloprost in hand-arm vibration syndrome. METHODS: We describe a clinical case of a male aged 53 years, who was a heavy smoker for 30 years and a mason working with vibrating tools since 1962. He presented with a history of 10 years of atta...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1093/occmed/kqh035

データ提供:米国国立医学図書館(NLM)

Iloprost for Hand-Arm Vibration Syndrome

Hand-arm vibration syndrome (HAVS) is a condition that affects workers who use vibrating tools for long periods. It can lead to vascular problems, numbness, and pain in the hands and arms. This case study investigated the efficacy of iloprost, a drug used to treat vascular problems, in a patient with advanced HAVS.

Iloprost Shows Promise in Treating HAVS

The patient in this study experienced significant improvement in symptoms and function after receiving intravenous iloprost. His trophic skin lesions disappeared, and his microcirculatory perfusion tests improved. Importantly, the treatment was well-tolerated, with no significant side effects.

Hope for a Challenging Condition

This case study suggests that iloprost might be a promising treatment option for advanced HAVS. Further research is needed to confirm its efficacy and safety in a larger population. For those who work with vibrating tools, this study offers a glimmer of hope for managing a challenging condition that can significantly impact their lives.

Dr.Camel's Conclusion

Just as a camel adapts to the harsh desert environment, this study shows how iloprost can potentially help individuals with advanced HAVS adapt to their condition. It's a promising step towards finding effective treatments for this debilitating disease.

Date :
  1. Date Completed 2004-10-04
  2. Date Revised 2019-05-13
Further Info :

Pubmed ID

15190165

DOI: Digital Object Identifier

10.1093/occmed/kqh035

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.